NIH Director's Blog: Drug Development

NOVEMBER 16, 2021

That progress includes the development of life-preserving monoclonal antibody infusions and repurposing existing drugs , to which NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV ) public-private partnership has made a major contribution. But would it work to treat COVID-19 in an infected person?

Clinical Trials 52

Clinical Trials Virus Hospitals FDA 52

PLOS: DNA Science

JULY 27, 2023

That information led, thanks to vaccine shelved from the first SARS circa 2003, to the rapid development and deployment of mRNA vaccines against the new infectious disease. The owners of the felines all reported feeding their pets raw meat, and samples of the meat revealed not only flu virus genetic material, but also infectious virus.

Disease 92

Disease DNA Virus RNA 92

The Pharma Data

NOVEMBER 18, 2020

Lab tests that look for the coronavirus’s genetic material using a technique called polymerase chain reaction (PCR) are still considered the gold standard for detecting the virus. ” COVID Vaccines Move Closer to Emergency Use Approval. announced earlier this week that early results show its coronavirus vaccine is 94.5

FDA Approval 52

FDA Approval FDA Vaccine Virus 52

The Pharma Data

SEPTEMBER 1, 2021

MOVe-AHEAD (MK-4482-013) ( NCT04939428 ) is a Phase 3 multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered molnupiravir compared to placebo in preventing the spread of SARS-CoV-2, the virus that causes COVID-19, within households. About Molnupiravir.

Laboratories 52

Laboratories Virus Clinical Trials Research Laboratories 52

Drug Discovery World

AUGUST 1, 2023

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the generation of proteins in the body.

RNA 130

RNA Vaccine Drugs Disease 130

The Pharma Data

MARCH 22, 2022

Co-administration with a low dose of ritonavir helps slow the metabolism, or breakdown, of nirmatrelvir in order for it to remain active in the body for longer periods of time at higher concentrations to help combat the virus. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.

Treatment 52

Treatment Virus Hospitals Therapies 52

Broad Institute

JANUARY 30, 2024

He has also emerged in recent years as a skilled and relatable science communicator, renowned for his efforts at Broad and beyond during the COVID-19 pandemic to unpack the fast-moving research on the new virus in an accessible way and give practical advice about masking, vaccines, and other public health measures.

Hospitals 137

Hospitals Medical Schools Virus Science 137

Codon

AUGUST 27, 2024

Consider Alice, a 49-year-old woman (and hypothetical patient) who walked into a hospital in Puerto Rico with joint pain, a headache, nausea, and a low fever. While Alice was lucky that her infections were identified at the hospital, it would have been even better had they been identified before she arrived.

DNA 84

DNA Hospitals Laboratories Virus 84

The Pharma Data

JULY 29, 2021

Hepatitis B virus (“HBV”) and hepatitis delta virus (“HDV”) product sales increased 8% to $237 million for the second quarter 2021 compared to the same period in 2020. Sales of Veklury are generally affected by COVID-19 related rates of infections, hospitalizations and vaccinations. for the same period in 2020.

Science 52

Science Production Treatment FDA 52

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 13, 2021

13, 2021 — A single-shot COVID-19 vaccine from Johnson & Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. vaccination efforts. Aaron Glatt, chair of the department of medicine and a hospital epidemiologist at Mount Sinai South Nassau Hospital in Oceanside, N.Y.

Vaccine 40

Vaccine Trials Immune Response Clinical Trials 40

Codon

SEPTEMBER 29, 2024

But, regardless of which was first, they all operated with the same core data as their mechanism for understanding life: messenger RNA ( mRNA ). On the surface, they hadn't deviated much from the early 2020s: a virus infected a cell and released the genetic therapy hidden within. But the differences racked up the closer one looked.

Engineering 125

Engineering Virus DNA Therapies 125

Broad Institute

DECEMBER 6, 2023

Using single-cell RNA sequencing to analyze gene expression in individual cells, the researchers have found how 86 major cytokines affect 17 immune cell types in mice. I hope our approach helps scientists make sense of any immune process, vaccine, disease, or therapy response, so that one can infer which cytokines are contributing to it.

Immune Response 138

Immune Response RNA Medical Schools Disease 138

Codon

APRIL 9, 2023

Small snippets of double-stranded RNA were sprayed onto hot pepper plants to control a pest, called Frankliniella occidentalis. The RNA strands shut down a specific gene in the insects, and killed half after 7 days. RNA may offer a safer form of pest control in the future. npj Vaccines. Robinson A.O. Nature Biotechnology.

Therapies 52

Therapies RNA Engineering Vaccine 52

The Pharma Data

NOVEMBER 30, 2020

(Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis.

Vaccine 52

Vaccine FDA Clinical Trials Disease 52

PLOS: DNA Science

MARCH 30, 2023

It is also difficult to identify with standard laboratory methods,” summed up Mahmoud Ghannoum, director of the Center for Medical Mycology at University Hospitals Cleveland Medical Center. Comparing genome sequences is important because they provide a 4-letter language in the bases A, C, G, and T (for DNA) or A, C, G, and U (for RNA).

DNA 52

DNA Hospitals Laboratories Virus 52

The Pharma Data

DECEMBER 27, 2020

Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study of monoclonal antibody VIR-7831 for hospitalized adults with COVID-19. Galidesivir is a broad-spectrum antiviral, an adenosine nucleoside analog that blocks viral RNA polymerase. Here’s a look. COVID-19-Related.

Clinical Trials 52

Clinical Trials Trials Therapies RNA 52

The Pharma Data

MARCH 20, 2021

Biogazelle, an innovative bioanalytical services company offering RNA and. Ghent University Hospital for SARS-CoV-2 virus screening. study RNA virus replication and virus-host interactions and in particular the use of single-cell proteomics to aid in this research. Bioinformatics in the Faculty.

Laboratories 52

Laboratories Virus RNA Bioinformatics 52

The Pharma Data

JANUARY 7, 2021

.” Armstrong told the Post that the CDC hopes to more than double the number of genomic sequences of the virus posted on public websites within the next two weeks. Herd immunity will be reached when the virus encounters enough people with immunity that it dies out. ” Hospitalizations reach new records. But the U.S.

Virus 52

Virus Hospitals Vaccine RNA 52

PLOS: DNA Science

DECEMBER 21, 2023

I am grateful to PLoS for giving me this voice for more than a decade, and free reign to cover anything that even remotely involves DNA or RNA. My third COVID article was perhaps the most cited, from February 20 of that first year, COVID-19-vaccine-will-close-in-on-the-spikes. COVID posts number more than 100.

DNA 105

DNA Vaccine Science Therapies 105

The Pharma Data

NOVEMBER 9, 2020

9, 2020 — A coronavirus vaccine developed by Pfizer and the German biotechnology firm BioNTech was more than 90 percent effective at protecting people from COVID-19, an interim analysis released Sunday shows. It is the strongest signal yet that a vaccine could help bring the pandemic to an end in record time. MONDAY, Nov.

Vaccine 52

Vaccine Virus RNA Hospitals 52

The Pharma Data

NOVEMBER 10, 2020

In a statement, the FDA said its approval of the antibody treatment, called bamlanivimib, is solely for people newly infected with coronavirus “who are at high risk for progressing to severe COVID-19 and/or hospitalization.” Pfizer vaccine 90 percent effective, early data shows.

Treatment 52

Treatment Vaccine Hospitals RNA 52

The Pharma Data

DECEMBER 23, 2020

and the Trump Administration were close to a deal on Tuesday that would get more of the company’s coronavirus vaccine to Americans in the coming year. So far, only two pharmaceutical companies — Pfizer and Moderna — have won emergency approval for their COVID-19 vaccines. WEDNESDAY, Dec.

Vaccine 52

Vaccine Government Virus Medical Schools 52